Fig. 1 · Structure

Documents & Downloads

MCOPPB trihydrochloride

Cat. No. A10561 CAS 1108147-88-1

NOP receptor agonist

MCOPPB is a compound which acts as a potent and selective agonist for the nociceptin receptor, with a pKi of 10.07.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

MCOPPB trihydrochloride Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of MCOPPB trihydrochloride from 2 published references. In vivo models include adult Sprague Dawley rats.

MCOPPB trihydrochloride In Vitro Studies

Neonatal mouse cardiomyocytes were treated with MCOPPB at 0.5 μM. Average cardiomyocyte size was 33.8 ± 3.4 μm2 without treatment versus 30.6 ± 1.1 μm2 with MCOPPB (p = 0.20). [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

MCOPPB and neonatal cardiomyocyte size

Cell-based study · Neonatal mouse cardiomyocytes (p3) [1]

Neonatal mouse cardiomyocytes were treated with MCOPPB at 0.5 μM. Average cardiomyocyte size was 33.8 ± 3.4 μm2 in the no-treatment group versus 30.6 ± 1.1 μm2 in the MCOPPB group (p = 0.20).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Average cardiomyocyte sizecardiomyocyte size no treatment, 33.8 ± 3.4 μm2 vs. MCOPPB group, 30.6 ± 1.1 μm2[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM
Exposure duration
at day 1 and day 2, and immunostained with troponin T at day 3
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: MCOPPB

The paper names MCOPPB without stating the salt or form; not verified as the trihydrochloride form supplied as A10561. No dose conversion or lot validation.

3. Results > 3.2. In Vitro Experiments (S70); Figure 5 legend (S173, S175)

Average cardiomyocyte size: Average cardiomyocyte size; comparator: no-treatment group — Figure 5 legend (S175)

MCOPPB trihydrochloride In Vivo Studies

Adult Sprague Dawley rats received MCOPPB by intraperitoneal injection after coronary artery ligation. Ejection fraction significantly improved with MCOPPB compared with saline at euthanasia. In CD-1 mice, intraperitoneal MCOPPB before formalin injection produced dose-dependent antinociceptive effects during the second phase compared with vehicle. [1,2]

MCOPPB and ejection fraction after coronary artery ligation

Animal study · Adult Sprague Dawley rats [1]

Adult Sprague Dawley rats received MCOPPB by intraperitoneal injection after coronary artery ligation. Ejection fraction significantly improved with MCOPPB compared with saline at euthanasia.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ejection fractionejection fraction 67 ± 3 vs. 43 ± 2[1]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
Three weeks after the coronary artery ligation, normal saline or MCOPPB (2.5 mg/kg/day) intraperitoneal injection was started, and continued 5 days per week for 3 months
Vehicle
normal saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MCOPPB 2.5 mg/kg/daysalinethe ejection fraction significantly improved in the MCOPPB group (MCOPPB vs. saline at 2 months’ follow-up, 58 ± 3 vs. 45 ± 2, p < 0.001; MCOPPB vs. saline at euthanasia, 67 ± 3 vs. 43 ± 2, p < 0.001)[1]
MCOPPB 2.5 mg/kg/day
Model: Adult Sprague Dawley rats
Methods and source locations

Compound reported in the paper: MCOPPB

The paper names MCOPPB without stating the salt or form; not verified as the trihydrochloride form supplied as A10561. No dose conversion or lot validation.

2. Materials and Methods > 2.1. Animals (S4, S6, S9); 2. Materials and Methods > 2.2. ORL1 Activator (S17); 2. Materials and Methods > 2.3. Treatment (S20); 3. Results > 3.1. In Vivo Experiments (S50)

ejection fraction: ejection fraction; comparator: saline — 3. Results > 3.1. In Vivo Experiments (S50)

MCOPPB 2.5 mg/kg/day · 2. Materials and Methods > 2.3. Treatment (S20); 3. Results > 3.1. In Vivo Experiments (S50)

MCOPPB and formalin-induced pain behavior

Animal study · CD-1 mice; 8 mice/group [2]

CD-1 mice received MCOPPB at 10 mg/kg i.p. before formalin injection. MCOPPB produced dose-dependent antinociceptive effects compared with vehicle, with effects reported during the second phase.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cumulative formalin–induced pain behavior during the I° and II° phases; second phaseReported result MCOPPB produced dose−dependent antinociceptive effects; 10 mg/kg i.p., for the II° phase; ED50 formalin 1.10 mg/kg[2]

Conditions shared by the study groups

Route
i.p.
Treatment course
30 min before formalin injection; during 15–45 min
Vehicle
water containing 1% DMSO and 0.3% cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MCOPPB 10 mg/kgvehicle treated animalsMCOPPB produced dose−dependent antinociceptive effects; 10 mg/kg i.p., for the II° phase; ED50 formalin 1.10 mg/kg[2]
MCOPPB 10 mg/kg
Model: CD-1 mice; 8 mice/group
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: MCOPPB

Evidence for MCOPPB as the hydrate, trihydrochloride form reported in the paper, not the trihydrochloride form supplied as A10561; no salt equivalence, dose conversion or lot validation.

Materials and Methods > Drugs (S4); Materials and Methods > Formalin Test (S44, S47, S48); Materials and Methods > Data Analysis (S58); Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); FIGURE 6 legend (S109, S110, S111, S112); FIGURE 7 legend (S115); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)

Cumulative formalin–induced pain behavior during the I° and II° phases; second phase: Cumulative formalin–induced pain behavior during the I° and II° phases; second phase; comparator: vehicle treated animals — Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); FIGURE 6 legend (S110); FIGURE 7 legend (S115); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)

MCOPPB 10 mg/kg · Materials and Methods > Formalin Test (S47, S48); Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 1108147-88-1
Applications NOP receptor agonist
Formula C26H40N4
Molecular Weight 408.62
SMILES
CC1(N2CCC(N3C4=CC=CC=C4N=C3[C@H]5CNCCC5)CC2)CCCCCCC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MCOPPB trihydrochloride Research References

  1. [1] Pathan SS, Pugazenthi A, Dixon BREA, et al. Activation of a GPCR, ORL1 Receptor: A Novel Therapy to Prevent Heart Failure Progression. J Cardiovasc Dev Dis (2024). PMID: 39590198 DOI: 10.3390/jcdd11110355 Source material
  2. [2] Azevedo Neto J, Ruzza C, Sturaro C, et al. Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists. Front Neurosci (2021). PMID: 33859548 DOI: 10.3389/fnins.2021.657153 Source material

Added to your cart

View Cart Checkout
Loading...